Bi-epitope SPR surfaces: a solution to develop robust immunoassays

PLoS One. 2014 Nov 5;9(11):e112070. doi: 10.1371/journal.pone.0112070. eCollection 2014.

Abstract

Surface plasmon resonance (SPR)-based immunoassays have numerous applications and require high affinity reagents for sensitive and reliable measurements. We describe a quick approach to turn low affinity antibodies into appropriate capture reagents. We used antibodies recognizing human ephrin type A receptor 2 (EphA2) and a ProteOn XPR36 as a model system. We generated so-called 'bi-epitope' sensor surfaces by immobilizing various pairs of anti-EphA2 antibodies using standard amine coupling. The apparent binding affinities to EphA2 and EphA2 detection sensitivities of the bi-epitope and 'single-epitope' surfaces were then compared. For all antibody pairs tested, bi-epitope surfaces exhibited an ∼ 10-100-fold improvement in apparent binding affinities when compared with single-epitope ones. When pairing 2 antibodies of low intrinsic binding affinities (∼ 10(-8) M) and fast dissociation rates (∼ 10(-2) s(-1)), the apparent binding affinity and dissociation rate of the bi-epitope surface was improved up to ∼ 10(-10) M and 10(-4) s(-1), respectively. This led to an ∼ 100-200-fold enhancement in EphA2 limit of detection in crude cell supernatants. Our results show that the use of antibody mixtures in SPR applications constitutes a powerful approach to develop sensitive immunoassays, as previously shown for non-SPR formats. As SPR-based assays have significantly expanded their reach in the last decade, such an approach promises to further accelerate their development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / chemistry*
  • Antibody Affinity
  • Epitopes
  • Humans
  • Receptor, EphA2 / chemistry*
  • Surface Plasmon Resonance*

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Epitopes
  • Receptor, EphA2

Grants and funding

All work was funded by the authors' employer, MedImmune. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.